Harrow relaunches triamcinolone acetonide injectable suspension
Harrow announced the relaunch of triamcinolone acetonide injectable suspension (Triesence) 40 mg/mL, a preservative‑free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and for the treatment of ocular …